Insmed Inc (INSM)
68.15
-0.17
(-0.25%)
USD |
NASDAQ |
Nov 04, 16:00
68.45
+0.30
(+0.44%)
After-Hours: 20:00
Insmed Revenue (Quarterly): 93.42M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 93.42M |
| June 30, 2024 | 90.34M |
| March 31, 2024 | 75.50M |
| December 31, 2023 | 83.69M |
| September 30, 2023 | 79.07M |
| June 30, 2023 | 77.23M |
| March 31, 2023 | 65.21M |
| December 31, 2022 | 59.30M |
| September 30, 2022 | 67.73M |
| June 30, 2022 | 65.22M |
| March 31, 2022 | 53.11M |
| December 31, 2021 | 56.12M |
| September 30, 2021 | 46.76M |
| June 30, 2021 | 45.37M |
| March 31, 2021 | 40.21M |
| December 31, 2020 | 41.42M |
| September 30, 2020 | 43.64M |
| June 30, 2020 | 42.50M |
| March 31, 2020 | 36.86M |
| December 31, 2019 | 45.71M |
| September 30, 2019 | 38.88M |
| June 30, 2019 | 29.97M |
| March 31, 2019 | 21.90M |
| December 31, 2018 | 9.835M |
| September 30, 2018 |
| Date | Value |
|---|---|
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | 11.50M |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
36.86M
Minimum
Mar 2020
93.42M
Maximum
Sep 2024
60.42M
Average
57.71M
Median
Revenue (Quarterly) Benchmarks
| Fulcrum Therapeutics Inc | 80.00M |
| Alnylam Pharmaceuticals Inc | 500.92M |
| Eli Lilly and Co | 11.44B |
| Bioventus Inc | 151.22M |
| Entrada Therapeutics Inc | 94.69M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -220.52M |
| Total Expenses (Quarterly) | 292.17M |
| EPS Diluted (Quarterly) | -1.27 |
| Enterprise Value | 11.68B |
| Gross Profit Margin (Quarterly) | 77.34% |
| Profit Margin (Quarterly) | -236.0% |
| Earnings Yield | -8.14% |
| Normalized Earnings Yield | -7.585 |